Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dendritic cell vaccine (Mackay Memorial Hospital)
- Development stage
- Phase 2
- Lead developer
- 馬偕紀念醫院
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Dendritic cell vaccine (Mackay Memorial Hospital) is an autologous, cell-based cancer immunotherapy developed for the treatment of hepatocellular carcinoma (HCC). The vaccine is produced by isolating monocytes from the patient's peripheral blood, differentiating them into dendritic cells, and pulsing them with autologous tumor lysates derived from the patient's own tumor. These dendritic cells are matured using a cytokine cocktail containing recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and interleukin-4 (rhIL-4). The matured, antigen-loaded dendritic cells are then reintroduced into the patient to stimulate a specific cytotoxic T lymphocyte (CTL) response against HCC cells. Research at Mackay Memorial Hospital has also investigated the use of low-dose radiation to enhance the immunogenicity of the tumor cells used for the lysate.
- Other names
- Autologous tumor lysate-pulsed dendritic cell vaccineMackay Memorial Hospital HCC DC vaccine
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on Dendritic cell vaccine (Mackay Memorial Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dendritic cell vaccine (Mackay Memorial Hospital).